Skip to main content

Table 2 Univariate analysis of associations with clinical outcomes

From: Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients

Variables Total Event Median survival (mo) Log-rank P HR (95% CI) P
Association with PFS
 CTC
  0 26 14 18.1 < 0.001 Ref.  
   ≥ 1 37 31 5.0   4.02 (2.05–7.86) < 0.001
 NLR
   < 2.65 21 14 11.4 0.119 Ref.  
   ≥ 2.65 42 31 6.5   1.65 (0.87–3.12) 0.123
 PLR
   < 155.54 23 14 11.4 0.091 Ref.  
   ≥ 155.54 40 31 5.7   1.72 (0.91–3.24) 0.095
 Risk group
  CTC = 0 and NLR < 2.65 9 4 20.1 < 0.001 Ref.  
  CTC = 0 and NLR ≥ 2.65 17 10 12.2   1.92 (0.59–6.29) 0.279
  CTC ≥ 1 and NLR < 2.65 12 10 6.1   Ref.  
  CTC ≥ 1 and NLR ≥ 2.65 25 21 3.3   2.12 (0.97–4.61) 0.059
  CTC = 0 and PLR < 155.54 11 5 20.1 < 0.001 Ref.  
  CTC = 0 and PLR ≥ 155.54 15 9 17.9   1.42 (0.47–4.29) 0.531
  CTC ≥ 1 and PLR < 155.54 12 9 7.5   Ref.  
  CTC ≥ 1 and PLR ≥ 155.54 25 22 4.1   2.27 (1.02–5.08) 0.046
Association with OS
 CTC       
  0 26 5 NR 0.006 Ref.  
   ≥ 1 37 18 14.2   3.72 (1.37–10.06) 0.010
 NLR
   < 2.65 21 4 NR 0.023 Ref.  
   ≥ 2.65 42 19 17.7   3.27 (1.11–9.63) 0.031
 PLR
   < 155.54 23 5 NR 0.077 Ref.  
   ≥ 155.54 40 18 17.7   2.38 (0.88–6.43) 0.086
 Risk group
  CTC = 0 and NLR < 2.65 9 1 NR 0.002 Ref.  
  CTC = 0 and NLR ≥ 2.65 17 4 NR   3.12 (0.34–28.34) 0.313
  CTC ≥ 1 and NLR < 2.65 12 3 NR   Ref.  
  CTC ≥ 1 and NLR ≥ 2.65 25 15 9.1   3.79 (1.09–13.13) 0.036
  CTC = 0 and PLR < 155.54 11 2 NR 0.007 Ref.  
  CTC = 0 and PLR ≥ 155.54 15 3 NR   1.19 (0.20–7.18) 0.846
  CTC ≥ 1 and PLR < 155.54 12 3 NR   Ref.  
  CTC ≥ 1 and PLR ≥ 155.54 25 15 13.7   2.85 (0.82–9.86) 0.098
  1. CTC circulating tumor cell; NLR neutrophil-to-lymphocyte ratio; PLR platelet-to-lymphocyte ratio; PFS progression free survival; OS overall survival; NR not reached; HR hazard ratio; CI confidence interval